Dose response to rhCC10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: Physiological, inflammatory, and kinetic profiles

Journal of Applied Physiology

Volumn 99, Issue 6, 2005, Pages 2204-2211

  Shashikant, Beth N ^a   Miller, Thomas L ^a,b   Welch, Richard W ^c   Pilon, Aprile L ^c   Shaffer, Thomas H ^a,b   Wolfson, Maria M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c Claragen Incorporated   (United States)

Author keywords

Bronchopulmonary dysplasia; Clara cell secretory protein; Cytokines; Mechanical ventilation

Indexed keywords

BERACTANT; CLARA CELL PROTEIN; CLARAGEN; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; MYELOPEROXIDASE; RECOMBINANT HUMAN CLARA CELL SECRETORY PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; CYTOKINE PRODUCTION; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; LAMB; LUNG DYSPLASIA; LUNG FUNCTION; LUNG MECHANICS; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL PRODUCTS; CHEMOTHERAPY, ADJUVANT; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFANT, NEWBORN; LUNG; PULMONARY SURFACTANTS; PULMONARY VENTILATION; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SHEEP; TREATMENT OUTCOME; UTEROGLOBIN;

EID: 28044440058     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00246.2005     Document Type: Article

References (42)

1. Al-Rahmani A, Awad K, Miller TF, Wolfson MR, and Shatter TH. Effects of partial liquid ventilation with perfluorodecalin in the juvenile rabbit lung after saline injury. Crit Care Med 28: 1459-1464, 2000.
2. American Academy of Pediatrics, Committee on Fetus and Newborn, and Canadian Paediatric Society, Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 109: 330-338, 2002.
3. Bhutani VK, Sivieri EM, Abbasi S, and Shatter TH. Evaluation of neonatal pulmonary mechanics and energetics: a two-factor least mean square analysis. Pediatr Pulmonol 4: 150-158, 1988.
4. Boynton BR, Carlo WA, and Jobe AH (Editors). New Therapies for Neonatal Respiratory Failure. New York: Cambridge University Press, 1994.
5. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the protein-dye binding. Anal Biochem 72: 48-54, 1976.
6. Chandra S, Davis JM, Drexler S, Kowalewska J, Chester D, Koo HC, Pollack S, Welch R, Pilon A, and Levine CR. Safety and efficacy of intratracheal recombinant human Clara cell protein in a newborn piglet model of acute lung injury. Pediatr Res 54: 509-515, 2003.
7. Chen LC, Zhang Z, Myers AC, and Huang SK, Cutting edge: altered pulmonary eosinophilic inflammation in mice deficient for Clara cell secretory 10-kDa protein. J Immunol 167: 3025-3028, 2001.
8. Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 82: 683-691, 1988.
9. Couser RJ, Ferrara TB, Ebert J, Hoekstra RE, and Fangman JJ. Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease. J Pediatr 116: 119-124, 1990.
10. Davis JM, Veness-Meehan K, Notter RH, Bhutani VK, Kendig JW, and Shapiro DL. Changes in pulmonary mechanics after the administration of surfactant to infants with respiratory distress syndrome. N Engl J Med 319: 476-479, 1988.
11. Dierynck I, Bernard A, Roels H, and De Ley M. The human Clara cell protein: biochemical and biological characterization of a natural immunosuppressor. Mult Scler 1: 385-387, 1996.
12. Halliday HL, Ehrenkranz RA, and Doyle LW. Delayed (>3 wk) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 1: CD001145, 2003.
13. Hayashida S, Harrod KS, and Whitsett JA. Regulation and function of CCSP during pulmonary Pseudomonas aeruginosa infection in vivo. Am J Physiol Lung Cell Mol Physiol 279: L452-L459, 2000.
14. Ikegami M and Jobe AH. Injury responses to different surfactants in ventilated premature lamb lungs. Pediatr Res 51: 689-695, 2002.
15. Imai Y, Kawano T, Iwamoto S, Nakagawa S, Takata M, and Miyasaka K. Intratracheal anti-tumor necrosis factor-α antibody attenuates ventilator-induced lung injury in rabbits. J Appl Physiol 87: 510-515, 1999.
16. Jobe AH and Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163: 1723-1729, 2001.
17. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res 46: 641-643, 2000.
18. Kendig JW, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, Sinkin RA, Bartoletti A, Dweck HS, Horgan MJ et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med 324: 865-871, 1991.
19. 2-mediated inhibition of fibroblast migration in vitro. Am J Respir Crit Care Med 152: 290-297, 1995.
20. Levin SW, Butler JD, Schumacher UK, Wightman PD, and Mukherjee AB. Uteroglobin inhibits phospholipase A2 activity. Life Sci 38: 1813-1819, 1986.
21. Levine CR, Gewolb IH, Allen K, Welch R, Melby J, Pollack S, Shaffer TH, Pilon A, and Davis JM. The safety, pharmacokinetics and anti-inflammatory effects of intratracheal recombinant human clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 58: 15-21, 2005.
22. Mantile G, Miele L, Cordella-Miele E, Singh G, Katyal SL, and Mukherjee AB. Human Clara cell 10-kDa protein is the counterpart of rabbit Uteroglobin. J Biol Chem 268: 20343-20351, 1993.
23. Mason RJ, Greene K, and Voelker DR. Surfactant protein A and surfactant protein D in health and disease. Am J Physiol Lung Cell Mol Physiol 275: L1-L13, 1998.
24. Miller TL, Nordby BA, Melby J, Pilon A, Shaffer TH, and Wolfson MR. Comparison of intratracheal (IT) vs. intravenous (IV) administration of rhCC10 therapy in acute lung injury (ALI): physiologic, inflammatory and kinetic profiles (Abstract). Pediatr Res 51: 464A, 2002.
25. Nordby BA, Miller TL, Melby J, Pilon A, Shaffer TH, and Wolfson MR. rh-CC10-augmented surfactant (SF) therapy in acute lung injury (ALI): physiological and inflammatory profile (Abstract). Pediatr Res 51: 469A, 2002.
26. Northway WH Jr. An introduction to bronchopulmonary dysplasia. Clin Perinatol 19: 489-495, 1999.
27. Notter RH, Egan EA, Kwong MS, Holm BA, and Shapiro D. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: effects of dose, dispersion technique and gestational age. Pediatr Res 19: 569-577, 1985.
28. Pilon A. Rationale for the development of recombinant human CC10 as a therapeutic for inflammatory and fibrotic disease. Ann N Y Acad Sci 923: 280-299, 2000.
29. Ramsay PL, DeMayo FJ, Hegemier SE, Wearden ME, Smith CV, and Welty SE. Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia. Am J Respir Crit Care Med 164: 155-161, 2001.
30. Rosseau S, Hammerl P, Maus U, Gunther A, Seeger W, Grimminger F, and Lohmeyer J. Surfactant protein A down-regulates proinflammatory cytokine production evoked by Candida albicans in human alveolar macrophages and monocytes. J Immunol 163: 4495-4502, 1999.
31. Schierwagen C, Bylund-Fellenius A, and Lundberg C. Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J Pharmacol Methods 23: 179-186, 1990.
32. Shah SS, Ohlsson A, Halliday HL, and Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2: CD002057, 2003.
33. Stamme C, Brasch F, von Bethmann A, and Uhlig S. Effect of surfactant on ventilation-induced mediator release in isolated perfused mouse lungs. Pulm Pharmacol 15: 455-461, 2002.
34. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll BJ, and National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. N Engl J Med 344: 95-101, 2001.
35. Tegtmeyer FK, Moller J, Richter A, Wilken B, and Fischer T. Plasma concentration of elastase-alpha 1-proteinase inhibitor complex in surfactant-treated preterm neonates with respiratory distress syndrome. Eur Respir J 7: 260-264, 1994.
36. van Kaam AH, Haitsma JJ, Dik WA, Naber BA, Alblas EH, De Jaegere A, Kok JH, and Lachmann B. Response to exogenous surfactant is different during open lung and conventional ventilation. Crit Care Med 32: 774-780, 2004.
37. Van Marter LJ, Allred EN, Leviton A, Pagano M, Parad R, Moore M, and Neonatology Committee for the Developmental Epidemiology Network. Antenatal glucocorticoid treatment does not reduce chronic lung disease among surviving preterm infants. J Pediatr 138: 198-204, 2001.
38. 2 inhibitory protein, uteroglobin. Biochem Pharmacol 37: 389-394, 1988.
39. Wagner MH, Sonntag J, Strauss E, and Obladen M. Complement and contact activation related to surfactant response in respiratory distress syndrome. Pediatr Res 45: 14-18, 1999.
40. Watterberg KML, Carmichael DF, Gerdes JS, Werner S, Backstrom C, and Murphy S. Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J Pediatr 125: 264-269, 1994.
41. Welk B, Malloy JL, Joseph M, Yao LJ, and Veldhuizen AW. Surfactant treatment for ventilation-induced lung injury in rats: effects on lung compliance and cytokines. Exp Lung Res 27: 505-520, 2001.
42. Wolfson MR, Brunelli L, Nordby-Shashikant B, Miller TL, Kazzaz A, Davis JM, and Shaffer TH. Perfluorochemical (PFC) augmented rhSOD delivery attenuates inflammation in acute lung injury. Pediatr Res 53: 554A, 2003.